Evidence map›Paper›PMID 27799869›Full record

ArticleClinical proteomics2016

Proteomic profiling of retinoblastoma by high resolution mass spectrometry.

Ravikanth Danda, Kalaivani Ganapathy, Gajanan Sathe, Anil K Madugundu, Sharavan Ramachandran, Uma Maheswari Krishnan, Vikas Khetan, Pukhraj Rishi, T S Keshava Prasad, Akhilesh Pandey and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination.International journal of molecular sciences · 2024
    Review
  5. Review
  6. Review
  7. Mass spectrometry-based retina proteomics.Mass spectrometry reviews · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Exosomes: Insights from Retinoblastoma and Other Eye Cancers.International journal of molecular sciences · 2020
    Review
  14. Biomarkers in retinoblastoma.International journal of ophthalmology · 2020
    Review
  15. Review
  16. Article
  17. Article
  18. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes.International journal of molecular sciences · 2018
    Review
  19. Review
  20. Update on pathology of retinoblastoma.International journal of ophthalmology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ravikanth DandaDepartment of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India ; Centre for Nanotechnology and Advanced Biomaterials, Shanmugha Arts, Science, Technology and Research Academy University, Tanjore, Tamilnadu India.
Kalaivani GanapathyDepartment of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India.
Gajanan SatheInstitute of Bioinformatics, International Technology Park, Bangalore, Karnataka 560066 India.
Anil K MadugunduInstitute of Bioinformatics, International Technology Park, Bangalore, Karnataka 560066 India.
Sharavan RamachandranDepartment of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India.
Uma Maheswari KrishnanCentre for Nanotechnology and Advanced Biomaterials, Shanmugha Arts, Science, Technology and Research Academy University, Tanjore, Tamilnadu India.
Vikas KhetanShri Bhagwan Mahavir Vitreoretinal Services and Ocular Oncology Services, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India.
Pukhraj RishiShri Bhagwan Mahavir Vitreoretinal Services and Ocular Oncology Services, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India.
T S Keshava PrasadInstitute of Bioinformatics, International Technology Park, Bangalore, Karnataka 560066 India.
Akhilesh PandeyMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA ; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA ; Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Subramanian KrishnakumarDepartment of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India.
Harsha GowdaInstitute of Bioinformatics, International Technology Park, Bangalore, Karnataka 560066 India.
Sailaja V ElchuriDepartment of Nano-Biotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamilnadu 600006 India.
Sankara Nethralaya · INInstitute of Bioinformatics · INJohns Hopkins University · USSASTRA University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetinoblastoma is an ocular neoplastic cancer caused primarily due to the mutation/deletion of RB1 gene. Due to the rarity of the disease very limited information is available on molecular changes in primary retinoblastoma. High throughput analysis of retinoblastoma transcriptome is available however the proteomic landscape of retinoblastoma remains unexplored. In the present study we used high resolution mass spectrometry-based quantitative proteomics to identify proteins associated with pathogenesis of retinoblastoma.

methodsWe used five pooled normal retina and five pooled retinoblastoma tissues to prepare tissue lysates. Equivalent amount of proteins from each group was trypsin digested and labeled with iTRAQ tags. The samples were analyzed on Orbitrap Velos mass spectrometer. We further validated few of the differentially expressed proteins by immunohistochemistry on primary tumors.

resultsWe identified and quantified a total of 3587 proteins in retinoblastoma when compared with normal adult retina. In total, we identified 899 proteins that were differentially expressed in retinoblastoma with a fold change of ≥2 of which 402 proteins were upregulated and 497 were down regulated. Insulin growth factor 2 mRNA binding protein 1 (IGF2BP1), chromogranin A, fetuin A (ASHG), Rac GTPase-activating protein 1 and midkine that were found to be overexpressed in retinoblastoma were further confirmed by immunohistochemistry by staining 15 independent retinoblastoma tissue sections. We further verified the effect of IGF2BP1 on cell proliferation and migration capability of a retinoblastoma cell line using knockdown studies.

conclusionsIn the present study mass spectrometry-based quantitative proteomic approach was applied to identify proteins differentially expressed in retinoblastoma tumor. This study identified the mitochondrial dysfunction and lipid metabolism pathways as the major pathways to be deregulated in retinoblastoma. Further knockdown studies of IGF2BP1 in retinoblastoma cell lines revealed it as a prospective therapeutic target for retinoblastoma.

Identifiers

PMID27799869
PMCPMC5080735
OpenAlexW2546118860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.